Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $46.92, for a total value of $938,400.00. Following the completion of the sale, the chief executive officer now directly owns 812,613 shares in the company, valued at $38,127,801.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Atara Biotherapeutics Inc (ATRA) traded down $0.60 during midday trading on Tuesday, hitting $44.80. The stock had a trading volume of 555,771 shares, compared to its average volume of 1,170,000. The stock has a market capitalization of $1,370.00, a P/E ratio of -12.91 and a beta of 2.71. Atara Biotherapeutics Inc has a 1-year low of $11.80 and a 1-year high of $49.90.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in Atara Biotherapeutics during the third quarter worth approximately $142,000. Russell Investments Group Ltd. purchased a new position in Atara Biotherapeutics during the third quarter worth approximately $170,000. Voya Investment Management LLC lifted its position in Atara Biotherapeutics by 16.2% during the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after buying an additional 1,651 shares in the last quarter. MetLife Investment Advisors LLC purchased a new position in Atara Biotherapeutics during the fourth quarter worth approximately $217,000. Finally, The Manufacturers Life Insurance Company lifted its position in Atara Biotherapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after buying an additional 1,369 shares in the last quarter. Institutional investors and hedge funds own 74.29% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.